Impact of Rantes from jawbone on Chronic Fatigue Syndrome.
Lechner, J, Huesker, K, Von Baehr, V · Journal of biological regulators and homeostatic agents · 2017
Quick Summary
This study investigated whether inflammation in the jawbone might contribute to ME/CFS. Researchers compared jawbone tissue from 21 ME/CFS patients with tissue from 19 healthy people and found that ME/CFS patients had significantly higher levels of inflammatory proteins (RANTES and FGF-2) in areas of jawbone that had undergone incomplete healing. The authors suggest that this hidden jawbone inflammation might be a previously unknown trigger for ME/CFS.
Why It Matters
If confirmed, this research could identify a treatable source of inflammation in ME/CFS patients, potentially opening new diagnostic and therapeutic avenues. The hypothesis that localized jawbone pathology contributes to systemic ME/CFS symptoms expands understanding of potential disease mechanisms and may explain why some patients report symptom improvement after dental interventions.
Observed Findings
FDOJ samples from CFS patients showed 30-fold mean overexpression of RANTES compared to healthy jawbone controls.
FDOJ samples from CFS patients showed 20-fold mean overexpression of FGF-2 compared to healthy controls.
All fatty necrotic and osteolytic jawbone samples in the CFS group displayed high expression of both RANTES and FGF-2.
CFS patient jawbone specimens were obtained from retromolar wisdom tooth extraction sites showing clinically evident fatty degeneration and osteonecrotic medullary changes.
Inferred Conclusions
FDOJ may represent a hidden chronic inflammatory source that contributes to ME/CFS pathogenesis through RANTES-mediated signaling pathway hyperactivation.
Improper or incomplete wound healing in the jawbone may serve as a previously unrecognized etiological factor in ME/CFS development.
Local jawbone inflammation could constitute a therapeutic target for certain ME/CFS patients.
Remaining Questions
Does treating or removing FDOJ actually improve ME/CFS symptoms in affected patients, or is the association merely correlative?
What mechanisms explain how localized jawbone inflammation drives systemic ME/CFS symptoms and fatigue?
Are specific ME/CFS patient subgroups more likely to have FDOJ, and how common is FDOJ in the general population?
What This Study Does Not Prove
This study does not prove that FDOJ causes ME/CFS—it only shows correlation in a small sample. The cross-sectional design cannot establish temporal relationships or rule out reverse causation. Additionally, elevated inflammatory markers in jawbone tissue do not necessarily establish that this tissue is the primary driver of systemic ME/CFS symptoms rather than a secondary manifestation.